{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:24Z","timestamp":1772177484173,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"am","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.therap.2021.05.010","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:21:33Z","timestamp":1622200893000},"page":"311-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["COVID-19 vaccines: A perspective from social pharmacology"],"prefix":"10.1016","volume":"76","author":[{"given":"Jean-Louis","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"de Canecaude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2021.05.010_bib0080","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2021.05.010_bib0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2021.05.010_bib0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.therap.2021.05.010_bib0095","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"10.1016\/j.therap.2021.05.010_bib0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an\u00a0rAd26\u00a0and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2021.05.010_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2021.05.004","article-title":"Efficacy of Covid-19 vaccines: from clinical trials to real life","author":"Deplanque","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2021.05.010_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2021.05.003","article-title":"French organization for the pharmacovigilance of COVID-19 vaccines: a major challenge","author":"Lacroix","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2021.05.010_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2021.05.002","article-title":"Evaluation of Covid-19 vaccines: pharmacoepidemiological aspects","author":"Pariente","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2021.05.010_bib0120","first-page":"420","article-title":"Social pharmacology: a new topic in clinical pharmacology","volume":"57","author":"Montastruc","year":"2002","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.therap.2021.05.010_bib0125","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-005-0925-6","article-title":"\u201cMedicamentation\u201d of society, non-diseases and non-medications: a point of view from social pharmacology","volume":"61","author":"Mbongue","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.05.010_bib0130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41590-019-0488-9","article-title":"Vaccine hesitancy and coercion: all eyes on France","volume":"20","author":"Ward","year":"2019","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.therap.2021.05.010_bib0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.therap.2018.12.005","article-title":"How to improve vaccine acceptability (evaluation, pharmacovigilance, communication, public health, mandatory vaccination, fears and beliefs)","volume":"74","author":"Dutilleul","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2021.05.010_bib0140","doi-asserted-by":"crossref","first-page":"113414","DOI":"10.1016\/j.socscimed.2020.113414","article-title":"The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue","volume":"265","author":"Ward","year":"2020","journal-title":"Social Sci Med"},{"key":"10.1016\/j.therap.2021.05.010_bib0145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.therap.2020.05.012","article-title":"Is the drug a scientific, social or political object?","volume":"75","author":"Bordet","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2021.05.010_bib0150","series-title":"Covid-19 vaccines: ethical, legal and practical considerations. Resolution 2361","author":"Council of Europe","year":"2021"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721001451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721001451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:37Z","timestamp":1758567277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721001451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0040595721001451"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.05.010","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccines: A perspective from social pharmacology","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}